By Michael Monostra
The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker.
At the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Richard E. Pratley, MD, a Healio | Endocrine Today Co-editor and the Samuel E. Crockett chair in diabetes research and medical director at AdventHealth Diabetes Institute, discussed the history of incretin-based therapies and continuing advances today. Read the article in Healio.